Remarkable response of non‐small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis

Remarkable response of non‐small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis

Abstract Nintedanib is a multi‐target receptor tyrosine kinase inhibitor that reduces the decline in forced vital capacity (FVC) and prevents acute exacerbations in idiopathic pulmonary fibrosis (IPF), which is a risk factor for lung cancer. However, it remains unclear whether nintedanib is an effec...

Full description

Bibliographic Details
Main Authors: Yoshiro Kai, Masayuki Matsuda, Atsuhiko Fukuoka, Shigeto Hontsu, Motoo Yamauchi, Masanori Yoshikawa, Shigeo Muro
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Thoracic Cancer
Subjects:
CT‐guided biopsy
idiopathic pulmonary fibrosis
lung cancer
nintedanib
non‐small cell carcinoma
Online Access:https://doi.org/10.1111/1759-7714.13935

Internet

https://doi.org/10.1111/1759-7714.13935

Similar Items